.mw-parser-output .hidden-begin{box-sizing:border-box;width:100%;padding:5px;border:none;font-size:95%}.mw-parser-output .hidden-title{font-weight:bold;line-height:1.6;text-align:left}.mw-parser-output .hidden-content{text-align:left}You can help expand this article with text translated from
the corresponding article in Italian. (January 2023) Click [show] for important translation instructions.
Machine translation, like
DeepL or
Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide
copyright attribution in the
edit summary accompanying your translation by providing an
interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Italian Wikipedia article at [[:it:Istituto nazionale per le malattie infettive]]; see its history for attribution.
You should also add the template ((Translated|it|Istituto nazionale per le malattie infettive)) to the
talk page.
For more guidance, see
Wikipedia:Translation.
The Lazzaro Spallanzani National Institute for Infectious Diseases (Italian: Istituto nazionale per le malattie infettive "L. Spallanzani") is an infectious disease hospital in the Italian city of Rome. The institute is named for the eighteenth-century Italian biologist Lazzaro Spallanzani.[citation needed]
It is the Italian national reference center for Ebola patients.[1]
During the COVID-19 pandemic, the Spallanzani Institute was the first research centre in Europe to isolate the genomic sequence of SARS-CoV-2 and upload it to GenBank.[2]
The team was composed of Maria Rosaria Capobianchi, Francesca Colavita, and Concetta Castilletti.[3]
The institute is working with biotech company ReiThera to test a COVID-19 vaccine candidate called GRAd-COV2, which is based on a modified gorilla adenovirus vector.[4]